BreCLIM-2 - A RCT Investigating Local Treatment for Breast Cancer Liver Metastases
Status:
Recruiting
Trial end date:
2029-12-31
Target enrollment:
Participant gender:
Summary
Breast cancer is the second most common cancer in Sweden with an incidence of 8000 per year.
The role of surgery for distant breast cancer metastasis beyond local lymph nodes remains
controversial even though some reports suggest there might be a survival benefit from
resection of oligometastases in the liver.
The purpose of this multicentre randomized clinical trial is to evaluate local treatment for
breast cancer liver metastases, compared to systemic oncological treatment only. The primary
endpoint is time to death from any cause, which will be compared using cox proportional
hazard regression. The secondary endpoints are three years survival, progression-free
survival, median overall survival and quality of life. The aim is also to evaluate overall
safety and predictive factors for survival during oncological and surgical treatment. The
overall purpose is to ameliorate treatment for advanced breast cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Umeå University
Collaborators:
Göteborg University Karolinska Institutet Linkoeping University Lund University Uppsala University